| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Review |
Department of Pathology, University Medical Center Utrecht, 3508 GA Utrecht, the Netherlands
ABSTRACT
The tumor suppressor protein p53 is a multifunctional transcription factor involved in the control of cell cycle progression, DNA integrity, and cell survival. p53 is mutated in half of all tumors and has a wide spectrum of mutation types. p53 mutants show different degrees of dominance over coexpressed wild-type p53, and loss of the wild-type p53 allele has been observed frequently. Several p53 mutants can exert oncogenic functions beyond their negative domination over the wild-type p53 tumor suppressor functions. These so-called gain-of-function effects, such as enhancement of tumorigenicity and therapy resistance, were investigated in p53-null cells. The possible mechanisms by which p53 mutants exert their gain-of-function effects are reviewed. The existence of functional gains of certain p53 mutants has important ramifications for tumor prognosis and cancer therapies.
This article has been cited by other articles:
|
|
 |
|
  B. Kumar, K. G. Cordell, N. D'Silva, M. E. Prince, M. E. Adams, S. G. Fisher, G. T. Wolf, T. E. Carey, and C. R. Bradford Expression of p53 and Bcl-xL as Predictive Markers for Larynx Preservation in Advanced Laryngeal Cancer Arch Otolaryngol Head Neck Surg, April 1, 2008; 134(4): 363 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. C. Wong, W. P. Tsang, P. Y. Chau, N. N. Co, T. Y. Tsang, and T. T. Kwok p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3 Mol. Cancer Ther., March 1, 2007; 6(3): 1054 - 1061. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Bihani, A. Chicas, C. P.-K. Lo, and A. W. Lin Dissecting the Senescence-like Program in Tumor Cells Activated by Ras Signaling J. Biol. Chem., January 26, 2007; 282(4): 2666 - 2675. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Peltonen, J A Welsh, and K H Vahakangas Is there a role for PCR-SSCP among the methods for missense mutation detection of TP53 gene? Human and Experimental Toxicology, January 1, 2007; 26(1): 9 - 18. [Abstract] [PDF]
|
|
|
|
 |
|
 S. P. Whitman, S. Liu, T. Vukosavljevic, L. J. Rush, L. Yu, C. Liu, M. I. Klisovic, K. Maharry, M. Guimond, M. P. Strout, et al. The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy Blood, July 1, 2005; 106(1): 345 - 352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. O'Farrell, P. Ghosh, N. Dobashi, C. Y. Sasaki, and D. L. Longo Comparison of the Effect of Mutant and Wild-Type p53 on Global Gene Expression Cancer Res., November 15, 2004; 64(22): 8199 - 8207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-G. Zhu, T. Hileman, Y. Ke, P. Wang, S. Lu, W. Duan, Z. Dai, T. Tong, M. A. Villalona-Calero, C. Plass, et al. 5-Aza-2'-deoxycytidine Activates the p53/p21Waf1/Cip1 Pathway to Inhibit Cell Proliferation J. Biol. Chem., April 9, 2004; 279(15): 15161 - 15166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Hernandez, L. A. Maddison, Y. Wei, F. DeMayo, T. Petras, B. Li, J. R. Gingrich, J. M. Rosen, and N. M. Greenberg Prostate-Specific Expression of p53R172L Differentially Regulates p21, Bax, and mdm2 to Inhibit Prostate Cancer Progression and Prolong Survival Mol. Cancer Res., December 1, 2003; 1(14): 1036 - 1047. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Mao, E. Seidlitz, K. Ghosh, Y. Murakami, and H. P. Ghosh The Cytoplasmic Domain Is Critical to the Tumor Suppressor Activity of TSLC1 in Non-Small Cell Lung Cancer Cancer Res., November 15, 2003; 63(22): 7979 - 7985. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Nesslinger, X.-B. Shi, and R. W. deVere White Androgen-independent Growth of LNCaP Prostate Cancer Cells Is Mediated by Gain-of-Function Mutant p53 Cancer Res., May 1, 2003; 63(9): 2228 - 2233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Y. Kim, K.-H. Lee, S. Chang, C. Chung, H.-W. Lee, J. Yim, and T. K. Kim Oncogenic Potential of a Dominant Negative Mutant of Interferon Regulatory Factor 3 J. Biol. Chem., April 18, 2003; 278(17): 15272 - 15278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Russo, M. Migliavacca, I. Zanna, M. R. Valerio, M. A. Latteri, N. Grassi, G. Pantuso, S. Salerno, G. Dardanoni, I. Albanese, et al. p53 Mutations in L3-Loop Zinc-binding Domain, DNA-Ploidy, and S Phase Fraction Are Independent Prognostic Indicators in Colorectal Cancer: A Prospective Study with a Five-Year Follow-Up Cancer Epidemiol. Biomarkers Prev., November 1, 2002; 11(11): 1322 - 1331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Smith, F. A. Carey, J. Beattie, M. J. V. Wilkie, T. J. Lightfoot, J. Coxhead, R. C. Garner, R. J. C. Steele, and C. R. Wolf Mutations in APC, Kirsten-ras, and p53---alternative genetic pathways to colorectal cancer PNAS, July 9, 2002; 99(14): 9433 - 9438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. El-Hizawi, J. P. Lagowski, M. Kulesz-Martin, and A. Albor Induction of Gene Amplification as a Gain-of-Function Phenotype of Mutant p53 Proteins Cancer Res., June 1, 2002; 62(11): 3264 - 3270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Smeds, P. Berggren, X. Ma, Z. Xu, K. Hemminki, and R. Kumar Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16INK4a and p14ARF ) and p53 genes are major targets for inactivation Carcinogenesis, April 1, 2002; 23(4): 645 - 655. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Stros, T. Ozaki, A. Bacikova, H. Kageyama, and A. Nakagawara HMGB1 and HMGB2 Cell-specifically Down-regulate the p53- and p73-dependent Sequence-specific Transactivation from the Human Bax Gene Promoter J. Biol. Chem., February 22, 2002; 277(9): 7157 - 7164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Yuan, C.-J. Yu, K.-T. Luh, S.-H. Kuo, Y.-C. Lee, and P.-C. Yang Aberrant p53 Expression Correlates With Expression of Vascular Endothelial Growth Factor mRNA and Interleukin-8 mRNA and Neoangiogenesis in Non-Small-Cell Lung Cancer J. Clin. Oncol., February 15, 2002; 20(4): 900 - 910. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
